Company Interview / Aussie MedTech IPO for your nerves

Dr. Julian Chick of ReNerve highlights the company's focus on nerve repair biotech as it plans to list on the ASX. ReNerve is targeting a $2.5 billion nerve injury market with its FDA-approved nerve cuff, offering improved outcomes for patients and convenience for surgeons.

Julian shares ReNerve's strategy for commercialisation in the US, targeting key medical centres to establish their infrastructure and increase product usage. The nerve cuff serves as a protective 'bandaid', aiding in the prevention of scarring and promoting nerve healing.

Looking globally, Julian outlines ReNerve's plans to expand beyond the US in 2025, aiming for approvals in regions like the Middle East, Central America, and Asia. The upcoming IPO aims to raise up to $7 million, facilitating the development of additional products and scaling up commercial operations.